FirstHealth of the Carolinas

Clinical Trial Details

Study Title: SystHERs Registry Study: An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer
Study Type: Observation
Study Condition: Breast Cancer
Investigator: Dr. Charles Kuzma
Phone: (910) 715-3500
Research Coordinator: Pam Mason
Phone: (910) 715-2200
Eligibility Criteria: Men or women, ages 18 and older, diagnosed with Stage I, II or III breast cancer. For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: Genentech
Study Rationale:
Study Purpose: This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer. Eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic therapy; patients may be enrolled up to 6 months after the diagnosis. Data will be collected for up to 8 years.
Study Link: http://clinicaltrials.gov/show/NCT01615068
   
 
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @ LinkedIn.com
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.